(Q41438152)

30 September 2017

1 reference

title

Do variations in molecular structure affect the clinical efficacy and safety of lipid-based amphotericin B preparations? (English)

1 reference

30 September 2017

0 references

1 reference

Mehta J

1

1 reference

30 September 2017

publication date

1 March 1997

1 reference

30 September 2017

1 reference

30 September 2017

volume

21

1 reference

30 September 2017

issue

3

1 reference

30 September 2017

page(s)

183-188

1 reference

Fungal infections in cancer patients: an international autopsy survey.

30 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900075-6

7 January 2021

Fungal sepsis in surgical patients

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900075-6

7 January 2021

Candida: an increasingly important pathogen in the nursery.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900075-6

7 January 2021

Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900075-6

7 January 2021

Candida infections in the intensive care unit.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900075-6

7 January 2021

Effects of sterols on the therapeutic efficacy of liposomal amphotericin B in murine candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900075-6

7 January 2021

Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900075-6

7 January 2021

Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900075-6

7 January 2021

Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900075-6

7 January 2021

Amphotericin B in liposomes: a novel therapy for histoplasmosis

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900075-6

7 January 2021

Lipid formulations of amphotericin B. Less toxicity but at what economic cost?

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900075-6

7 January 2021

Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900075-6

7 January 2021

Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900075-6

7 January 2021

Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900075-6

7 January 2021

Treatment of systemic fungal infections: recent progress and current problems

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900075-6

7 January 2021

Management of candidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900075-6

7 January 2021

10.1016/S0145-2126(96)00075-6

Identifiers

DOI

1 reference

30 September 2017

1 reference